Key result
Liposome-encapsulated Ac-SDKP improves post-MI LVEF by ~10 points and suppresses myocardial fibroinflammation in mice.
Why the study?
The clinical use of Ac-SDKP for myocardial remodeling is limited by rapid degradation of the endogenous peptide in vivo.
Does liposome-encapsulated Ac-SDKP improve cardiac function and prevent fibroinflammatory remodeling in a preclinical model of acute myocardial infarction?
Does liposome-encapsulated Ac-SDKP improve cardiac function and prevent fibroinflammatory remodeling in a preclinical model of acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Liposomal encapsulation of the endogenous peptide Ac-SDKP overcomes its rapid degradation, allowing intermittent dosing to deliver significant cardioprotection and preserved left ventricular function after myocardial infarction.
However, the rapid degradation of this endogenous peptide in vivo limits its clinical use. METHOD: To prolong its bioavailability, Ac-SDKP was encapsulated by phosphocholine lipid bilayers (liposomes) similar to mammalian cell membranes. The physical properties of the liposome structures were assessed by dynamic light scattering and scanning electron microscopy. The uptake of Ac-SDKP by RAW 264.7 macrophages and human and murine primary cardiac fibroblasts was confirmed by fluorescence microscopy and flow cytometry. Spectrum computerized tomography and competitive enzyme-linked immunoassays were performed to measure the ex vivo cardiac biodistribution of Ac-SDKP. The biological effects of this novel synthetic compound were examined in cultured macrophages and cardiac fibroblasts and in a murine model of acute myocardial infarction induced by permanent coronary artery ligation. RESULTS: A liposome formulation resulted in the greater uptake of Ac-SDKP than the naked peptide by cultured RAW 264.7 macrophages and cardiac fibroblasts. Liposome-delivered Ac-SDKP decreased fibroinflammatory genes in cultured cardiac fibroblasts co-treated with TGF-β1 and macrophages stimulated with LPS. Serial tissue and serum immunoassays showed the high bioavailability of Ac-SDKP in mouse myocardium and in circulation. Liposome-delivered Ac-SDKP improved cardiac function and reduced myocardial fibroinflammatory responses in mice with acute myocardial infarction. CONCLUSION: Encapsulation of Ac-SDKP in a cell membrane-like phospholipid bilayer enhances its plasma and tissue bioavailability and offers cardioprotection against ischemic myocardial injury. Future clinical trials can use this novel approach to test small protective endogenous peptides in myocardial remodeling.
No takes yet. Share an insight, caveat, or question.
Sonkawade et al. (2023) studied Acute myocardial infarction (n=70). Liposome-encapsulated Ac-SDKP (L-Ac-SDKP) vs. Vehicle (PBS) and free Ac-SDKP was evaluated on Left ventricular ejection fraction (p=0.0009). Liposome-encapsulated Ac-SDKP improved left ventricular ejection fraction and reduced myocardial fibroinflammatory responses in mice following acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: